Please use this identifier to cite or link to this item:
|Title:||Human pIgR mimetic peptidic ligand for affinity purification of IgM: Part I: Ligand design and binding mechanism|
Biomimetic peptidic ligand
|Citation:||Gautam, S., Loh, K.-C. (2013-01-04). Human pIgR mimetic peptidic ligand for affinity purification of IgM: Part I: Ligand design and binding mechanism. Separation and Purification Technology 102 : 173-179. ScholarBank@NUS Repository. https://doi.org/10.1016/j.seppur.2012.09.023|
|Abstract:||Synthetic peptides incorporating the complementarity determining region 2 (CDR2)-like loop of domain 1 of human polymeric immunoglobulin receptor (hpIgR-D1) were investigated for their interactions with human Immunoglobulin-M (hIgM) and other hIgs. pep14, a 14mer peptide, emerged as a unique biomimetic ligand with specificity to interact with hIgM and negligible affinity for hIgG, hIgE, hIgA1 and bovine serum albumin. Surface plasmon resonance-based binding studies between immobilized pep14 and fragments of hIgM molecule, namely Fc5μ and Fab, suggested that pep14 was binding to a motif in the constant domain 2 of hIgM. Modified peptides, pep13, pep5A and pep14A were investigated for their interaction with hIgM/ hIgG1 to elucidate the binding mechanism of pep14. Cysteine in pep14 was identified to be crucial for inducing thiophilic-like interactions between the ligand and hIgM while glutamic acid had a significant role in attributing specificity to the ligand to interact with hIgM. Circular dichroism studies suggested the absence of native β-hairpin structure in pep14. The ligand exhibited a more flexible conformation consisting mainly of a mixture of coil and turn. © 2012 Elsevier B.V. All rights reserved.|
|Source Title:||Separation and Purification Technology|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Sep 20, 2018
WEB OF SCIENCETM
checked on Sep 4, 2018
checked on Aug 3, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.